CO-FOUNDER, DIRECTOR, VOLUNTEER PRESIDENT
Professor of Neurochemistry at the University of Gothenburg, Sweden, and at University College London, UK, as well as the Head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy at the University of Gothenburg, Sweden
With a background in molecular biology and medicine, Dr. Zetterberg has spent the past 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. His research involves evaluation of biomarkers in cell and animal models, as well as in longitudinal studies of patients and healthy individuals. He has published more than 300 scientific articles and has received the Erik K. Fernström prize for young scientists and the Inga Sandeborg prize for research on Alzheimer’s disease.
Scientific Advisory Board
Chief Medical Officer and Head of Development at Denali Therapeutics Carole Ho currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics in San Francisco, CA. Denali Therapeutics is dedicated to therapeutic discovery and development of treatments for neurodegenerative diseases. Previously, Dr. Ho served as Vice President of Early Clinical Development at Genentech, where she headed the early clinical development for all indications outside of oncology, including neurology, ophthalmology, immunology, and infectious disease. She served as Group Medical Director of Rheumatology and Group Medical Director of Personalized Health Care for Inflammatory diseases. Prior to Genentech, she held a faculty appointment in the Department of Neurology at Stanford University and was subsequently a Medical Director at Johnson and Johnson.
Scientific Advisory Board
Director, Translational Neuroscience Center, Boston Children’s Hospital Professor of Neurology, Harvard Medical School Mustafa Sahin is currently the director of the Translational Neuroscience Center at Boston Children’s Hospital and Rosamund Stone Zander Chair professor of neurology at Harvard Medical School. Dr. Sahin serves as an expert for the Department of Neurology for Boston Children’s Hospital Precision Medicine Service. Work in his lab has identified the mechanisms by which tuberous sclerosis leads to miswiring of neurons in the brain and potential therapies for this disorder. Current research focuses on translating these preclinical findings into the clinic and developing treatments for epilepsy and autism associated with activation of the mTOR pathway. He directs two national consortia to study biomarkers and comparative pathobiology of TSC and related neurodevelopmental disorders.
Scientific Advisory Board
Harvard Medical School, Associate professor, Department of Neurology Beth Stevens is a Research Associate in Neurology at Boston’s Children’s Hospital, Associate Professor of Neurology at Harvard Medical School, and
institute member of the Broad Institute of MIT and Harvard. She is the Principal Investigator of the Stevens Lab. Stevens’s work has led her to the discovery of different roles of microglia and their relevance in neurological diseases. She is a recipient of the 2008 Smith Family Award for Excellence in Biomedical Research, a 2010 Dana Foundation Award (Brain and Immunoimaging), and a 2010 Ellison 28 of 37 Medical Foundation New Scholar in Aging award. Dr. Stevens received the Presidential Early Career Award for Scientists and Engineers in 2012. In 2015, she was selected for a MacArthur Foundation Fellowship.
Scientific Advisory Board
Harvard University, Professor of Stem Cell and Regenerative Biology Mark Fishman currently serves as Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service at
the MGH for patients with complex medical disorders. He was previously Chief of Cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital. He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences, Institute of Medicine. Fishman was appointed President of the newly founded Novartis Institutes for Bio Medical Research in 2002 to implement a new strategy in Novartis’ global drug discovery effort. During his tenure, NIBR discovered and brought through successful clinical trials of 90 new medicines in more than 120 indications. He is the author of over100 publications and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease.
Scientific Advisory Board
Professor of Neuroscience, Department of Brain and Cognitive Sciences at MIT Guoping Feng is the Poitras Professor of Neuroscience at the McGovern Institute for Brain Research in the Department of Brain and Cognitive Sciences at MIT and senior scientist at the Stanley Center for Psychiatric Research at Broad Institute, most notable for studying the synaptic mechanisms underlying psychiatric disease. In addition to developing many genetic-based imaging tools for the study of molecular mechanisms in the brain, he has generated and characterized rodent models of obsessive-compulsive disorder, autism spectrum disorders, and schizophrenia. Dr. Feng has also shown that some autism-like behaviors can be corrected in adult mice by manipulating the expression of the Shank3 gene.
Scientific Advisory Board
Chair, Harvard Department of Stem Cell and Regenerative Biology, Professor of Stem Cell and Regenerative Biology, Principal Faculty, Harvard Stem Cell Institute
Dr. Paola Arlotta is a professor of stem cell and regenerative biology at Harvard University, and chair of Harvard Department of Stem Cell and Regenerative Biology (HSCRB). She is a principal faculty member at the Harvard
Stem Cell Institute, where she is co-director of the neuroscience program, an institute member at the Broad Institute, and an associate member of the Stanley Center for Psychiatric Research at the Broad Institute. A leading neuroscientist, Dr. Arlotta is interested in understanding the molecular laws that govern the birth, differentiation, and assembly into working circuitry of clinically relevant neuron types in the cerebral cortex.
Scientific Advisory Board
Harvard University, Professor of Stem Cell and Regenerative Biology, Director of the Stanley Center for Psychiatric Research, Core Faculty member at the Broad Institute of Harvard and MIT. Steven Hyman is currently Director of the Stanley Center for Psychiatric Research and a member at the Broad Institute of MIT and Harvard. He is also the Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Dr. Hyman served as Provost of Harvard University, the University’s chief academic officer from 2001 to 2011. As Provost, he had a special focus on developing collaborative initiatives in the sciences and engineering spanning multiple disciplines and institutions. From 1996 to 2001, he served as director of the US National Institute of Mental Health (NIMH). Hyman is member of the National Academy of Medicine (NAM). In the past, he has chaired the National Academies of Sciences, Engineering, and Medicine Forum on Neuroscience and Nervous System Disorders (2012-2018); served as Editor of the Annual Review of Neuroscience (2001-2016); and served as President of the Society for Neuroscience (2015). Hyman serves as a Board Vice-Chair of the Charles A. Dana Foundation and as a Director of the Charles Revson Foundation. He is a Director of two biotechnology companies, Voyager Therapeutics and Q State Biosciences and serves on multiple Scientific Advisory Boards including Janssen, BlackThorn, and F-Prime. He is a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Association for the Advancement of Science, and a Distinguished Life Fellow of the American Psychiatric Association.
Director, Co-Chair of Finance Committee
Gerry is a principal in PwC’s Health Sciences Practice serving academic and research organizations across the healthcare continuum. Gerry joined the firm in 1988. He is responsible for leadership of the broad range of basic, translational and clinical research strategic and business planning services that PwC provides to academic and research organizations, specializing in development of synergistic partnerships and creation of new research ventures. Gerry serves as Partner on large engagements involving senior-level clients and interacts with the institution’s Board, financial leaders and political stakeholders. Gerry’s clients have included many of the top 50 Academic Medical Centers, major research universities and health systems, biotech organizations and pharmaceutical/device companies. Gerry leads PwC’s US Oncology Practice serving academic and commercial research organizations across the healthcare continuum and is responsible for leadership of the broad range of basic, translational and clinical research strategic and business planning services that PwC provides to academic and research organizations. He specializes in development of partnerships and creation of new research ventures. Over the last decade of Gerry’s leadership of the Health Sciences practice, clients
have included CEO’s, Presidents, Boards of Directors, prominent scientific leadership including Nobel Laureates, National Academy members, Lasker Award recipients, leaders of patient advocacy groups, heads of R&D, Chief Scientific Officers, CMO’s, the federal government and governors of several states. Over the past 5 years, Gerry’s teams have helped secure billions of dollars for biomedical 24 of 37 research and he has been instrumental in assisting prominent organizations such as the Knight Institute for Early Detection of Cancer and its clinical Director, Dr. Brian Druker, in developing strategies and plans to invest funds for the early detection of cancer. Among many strategic goals, they have focused on several key areas including: identifying the current limits of sensitivity and specificity and determining how they can be markedly improved to advance early detection; drawing clear distinctions between technological limitations and barriers that can be overcome versus absolute physical limits that define the boundaries of what is technically possible; contemplating which technologies are best suited for individual tumors and which could be applied broadly; development of cohorts suited to evaluating novel early detection technologies; the current understanding of the biology of transition from pre-malignancies to lethal malignancies; and what can be learned about early cancer recurrence, its prediction and detection, and how these things may inform earlier detection technologies.
Director, Co-Chair of the Scientific Advisory Board
Walter Ogier has more than thirty years of experience developing therapeutic medical products ranging from pharmaceuticals to medical devices, stem and immune cell therapies and gene therapies. Following receipt of a BA (chemistry) from Williams College and an MBA from the Yale School of Management, he served nearly a decade with Baxter Healthcare Corporation in marketing and business development roles supporting the global adoption of bone marrow and adult stem cell transplantation before joining Aastrom Biosciences, where he served as VP Marketing and supported the company’s successful IPO in 1997. He was subsequently President and CEO of Eligix (sold to BioTransplant in 2001), Genetix Pharmaceuticals (renamed bluebird bio, Nasdaq: BLUE), and he was President/CEO and co-founder of Acetylon Pharmaceuticals (sold to Celgene in 2016) and of Regenacy Pharmaceuticals (spun out of Acetylon at the time of the Celgene acquisition). Along with being a Director of the Mending Minds Foundation, Mr. Ogier currently serves as a director of Nemucore Medical Innovations, Regenacy Pharmaceuticals, Thetis Pharmaceuticals, Biothera Pharmaceuticals, and Katahdin Pharmaceuticals.
Director, Co-Chair of Community Development Committee
Stacey has 18 years of experience in executive search and has worked with life sciences clients ranging from venture backed companies to global Fortune 500 companies. She focuses on recruiting chief executive officers and board members as well as functional leaders, including scientific, commercial, and general management executives. In addition, she has expertise in recruiting professionals for venture capital firms focused on life sciences investing. Prior to joining ParkSquare, Stacey was a Director in the Life Sciences practice of J. Robert Scott, aglobal retained executive search firm. Previously, she was a search consultant with DHR International, the 5th largest executive search firm in the U.S and started her career with Battalia Winston, a boutique executive search firm, where she focused on the recruitment of senior level executives in a variety of industries. In addition
to her work at Park Square, Stacey sits on the Board of the Mending Minds Foundation (www.mminds.org), a foundation formed by parents, scientists and leading biotech executives, to fund research and clinical trials for pediatric immunopsychiatric conditions. Stacey holds a M.S. from Simmons College and a B.A. in International Relations and Public Policy from Syracuse University. She currently resides in Wellesley, Massachusetts with her husband, Adam, and two daughters, Peyton and Ava.
Co-founder, Director, Chair of Finance Committee
Todd is a Managing Partner of Tower Hill Financial Group. Prior to Tower Hill, Todd advised business owners and their executives in their personal and business financial matters. Todd has acted as Co-Founder and CEO/COO of two start-up companies and counseled owners of corporate aircraft on cost control strategies. In a prior role, he counseled non-profits and families of a private bank serving high net worth individuals and families.
Todd earned his BA from Colgate University and is an alumnus of The Belmont Hill School and active in the alumni affairs of both. He also serves on the Board of Directors of Riverside Community Care, a large non-profit healthcare and human services organizations in Massachusetts. Todd resides in Wellesley with his wife and three children.
Director, Chair of Scientific Advisory Board
Stacie Weninger is the President of FBRI. Prior to this position, she was the Senior Director of Science Programs for the Fidelity Foundations. In 2005, Dr. Weninger served as the Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, Dr. Weninger was a Senior Scientist at Cell Press for the journal Neuron. Before joining Cell Press, Dr. Weninger was a postdoctoral research fellow at Children’s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the Program in Neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Dr. Weninger was actively involved in undergraduate teaching, winning six teaching awards.
Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She currently chairs the Collaboration for Alzheimer’s Prevention; is President of Alzforum; serves as Chairman of the Board of Directors for Rugen Therapeutics; serves as a member of the Board of Directors for Aratome, Digital Cognition Technologies, and Target ALS; and she previously served as a founding member of the Board of Directors for Denali Therapeutics (NASDAQ: DNLI) as well as a member of the Board of Directors for Annexon Biosciences, BRI-Alzan (acquired by MeiraGTx), Enspectra, Inscopix, and Q-State Biosciences.
Co-founder, Director, Volunteer President
Tim Coleman is a chemist, biophysicist, inventor, philanthropist, and entrepreneur. He serves as the CEO of Nemucore Medical Innovations (nemucore.com) and as volunteer President of the Mending Minds Foundation (mminds.org). Tim is passionate about improving the health of people suffering from cancer and diseases of the brain. To this end he has co-founded organizations to help advance humanity’s collective ability to mitigate the harmful effects of these health conditions. His professional research efforts focus on the development of: innovative nanomedicines; immune programming platforms; a precision brain mapping system; targeted magnetic resonance imaging probes; precision small molecule therapeutics; and companion diagnostics based on system biology principles.
Always an athlete who loves to compete, Tim has become an avid runner and ultra-event competitor. He competes in 3-4 events annually using his participation to raise money for pediatric hematology oncology and breast cancer research. His personal goal is to run all six major marathons. Dr. Coleman received a Ph.D. in molecular biophysics /biochemistry from the Medical College of Virginia, an MBA from Boston University’s Questrom School of Business, and a B.S. degree in biochemistry from the Worcester Polytechnic Institute. He has authored numerous scientific papers, abstracts and patents. Tim lives in Wellesley, Massachusetts with his amazing wife, their high-energy daughter and loving dog.
Co-founder, Director, Chair of Community Development Committee
Amanda Peel Crowley received her BA from Colgate University and MA (education) from the University of Denver. Her career has focused on improving the lives of children, from work at the US FUND for UNICEF to teaching in many capacities, including in the New York City public schools, at an inclusion pre-school in Massachusetts and as ski instructor. She resides in Wellesley, MA and is actively involved in volunteering for school organizations. She is also involved in alumni giving for her alma mater Colgate as class gift chair with her husband Todd. She has three children diagnosed with PANDAS and co-founded the Mending Minds Foundation to advocate for world-class research to help children regain their childhoods.